Answers are grounded in this paper and cite their sources.
Exploratory findings show α-synuclein and age may modify visuospatial cognition in Parkinson's Disease, suggesting higher risk for decline.
AD and α-synuclein biomarkers show associations consistent with synergistic effects on visuospatial cognition in PD. These findings are exploratory and require replication in pre-specified independent cohorts. However, if validated, testing both biomarkers could help identify individuals at higher risk of early visuospatial decline and inform hypothesis-driven stratification in future clinical trials.
No takes yet. Share an insight, caveat, or question.
Ledingham et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: